[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588211":3},{"organization":4,"armGroups":7,"interventions":12,"overallOfficials":16,"centralContacts":21,"locations":26,"responsibleParty":47,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Beijing Tsinghua Chang Gung Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"inspection team",null,"Surgically resected liver tissue samples were sent to a third-party pathology slice reviewer for uniform reading, and a report on FGF19 expression results was issued and returned to the project team. The clinical data of the patient will be collected at the same time.",[13],{"type":6,"name":10,"description":14,"armGroupLabels":15,"otherNames":10},"This is an observational study and does not involve an intervention",[9],[17],{"name":18,"affiliation":19,"role":20},"ZHAOYING Resident physician, phD","Beijing Tsinghua Changgeng Hospital","PRINCIPAL_INVESTIGATOR",[22],{"name":18,"role":23,"phone":24,"phoneExt":10,"email":25},"CONTACT","86+13810943515","zya03937@btch.edu.cn",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Beijing Tsinghua Changgung Hospital","Beijing","China","CN",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},[39,41,42,45],{"name":40,"role":23,"phone":24,"phoneExt":10,"email":25},"ZHAO YING ZHAOYING, phD",{"name":40,"role":20,"phone":10,"phoneExt":10,"email":10},{"name":43,"role":44,"phone":10,"phoneExt":10,"email":10},"LI GONG LIGONG, phD","SUB_INVESTIGATOR",{"name":46,"role":44,"phone":10,"phoneExt":10,"email":10},"LI GUANGXIN LIGUANGXIN, phD",{"type":20,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"ZHAO YING","Principal Investigator","100588211",false,"NCT06938451","Relationship Between FGF19 Overexpression and Disease Prognosis","A Real-world Study of FGF19 Overexpression Status and Treatment Outcome and Prognosis in Advanced Hepatocellular Carcinoma","FGF19","Inclusion Criteria:\n\n* Age ≥18 years on the day of signing the informed consent form\n* Histologically or clinically confirmed diagnosis of intermediate to advanced HCC\n* Adequate tissue samples of previous liver cancer\n* Expected survival of more than 3 months\n\nExclusion Criteria:\n\n* Fibrous laminae or sarcomatoid HCC or mixed HCC-ICC, or other rare non-HCC pathologic subtypes\n* Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate","ALL","18 Years",{"count":60,"type":61},100,"ESTIMATED","3 Years","OBSERVATIONAL","A real-world study of FGF19 overexpression status and treatment outcome and prognosis in advanced hepatocellular carcinoma",[66],"Hepatocellular Carcinoma (HCC)",[55,68,69],"hepatocellular carcinoma","HCC","NOT_YET_RECRUITING","2025-04-14",{"date":73,"type":74},"2025-04-22","ACTUAL",{"date":76,"type":61},"2025-05-01",{"date":78,"type":61},"2028-12-31",{"name":5,"class":6},1]